Search Articles — Sudonull

Search Results

From the web

Sep 8, 2015 ·

https://www.chemoexperts.com/rvd.html

Sep 8, 2015 · RVd or VRd is given to alleviate myeloma symptoms and slow the progression of multiple myeloma, not to cure this disease. After treatment, patients who respond to RVd typically are either monitored, continue on to maintenance therapy, or proceed to bone marrow transplant.

Aug 1, 2022 ·

https://www.healthline.com/health/multiple-myeloma/vrd-multiple-myeloma

Aug 1, 2022 · VRd is a combination of drugs used to treat multiple myeloma. Learn about the regimen and possible side effects.

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for...

https://www.nejm.org/doi/full/10.1056/NEJMoa2400712

Jun 3, 2024 · Bortezomib, lenalidomide, and dexamethasone ( VRd ) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal...

Apr 27, 2022 ·

https://www.medicalnewstoday.com/articles/vrd-multiple-myeloma

Apr 27, 2022 · VRd is a treatment for multiple myeloma, a type of blood cancer. It is sometimes called RVd. VRd comprises the drugs Velcade, Revlimid, and dexamethasone.

Jul 30, 2026 ·

https://www.uptodate.com/contents/multiple-myeloma-initial-treatment

Jul 30, 2026 · Systemic therapy regimens for multiple myeloma: Bortezomib (Velcade), lenalidomide (Revlimid), and "low dose" dexamethasone ( VRd ) [1-3] Systemic therapy regimens for multiple myeloma: Lenalidomide (Revlimid) plus dexamethasone ( Rd ) [1] Systemic therapy regimens for multiple myeloma: Daratumumab, lenalidomide, and dexamethasone (DRd) [1,2]

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for...

https://www.nejm.org/doi/full/10.1056/NEJMoa2312054

Dec 12, 2023 · The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free ...

The DVRd Regimen | International Myeloma Foundation

https://www.myeloma.org/news-events/multiple-myeloma-news/dvrd-regimen

Apr 30, 2026 · At 54 months, approximately 68% of study patients in the DVRd arm remained progression-free vs. approximately 48% in the VRd arm. DVRd demonstrated a 43% lower risk of progression or death when compared to the VRd arm of the study.

Jul 10, 2026 ·

https://www.uptodate.com/contents/treatment-protocols-for-multiple-myeloma

Jul 10, 2026 · Systemic therapy regimens for multiple myeloma: Bortezomib (Velcade), lenalidomide (Revlimid), and "low dose" dexamethasone ( VRd ) [1-3] Systemic therapy regimens for initial treatment of multiple myeloma: Bortezomib, thalidomide, and dexamethasone ( VTd ) induction therapy [1,2]

Trending Now